Your browser doesn't support javascript.
loading
Single-center, retrospective study on changes in pain-relieving therapy after bone metastasis detection by bone scintigraphy in prostate cancer patients
Silva, Thamyrys Bessa; Cardoso, Marcella Araugio Soares; Ramim, Jayda Eiras; Bergmann, Anke; Pujatti, Priscilla Brunelli.
  • Silva, Thamyrys Bessa; Instituto Nacional de Câncer José Alencar Gomes da Silva. Medicina Nuclear. Rio de Janeiro. BR
  • Cardoso, Marcella Araugio Soares; Instituto Nacional de Câncer José Alencar Gomes da Silva. Medicina Nuclear. Rio de Janeiro. BR
  • Ramim, Jayda Eiras; Instituto Nacional de Câncer José Alencar Gomes da Silva. Medicina Nuclear. Rio de Janeiro. BR
  • Bergmann, Anke; Instituto Nacional de Câncer José Alencar Gomes da Silva. Programa de Epidemiologia Clínica. Rio de Janeiro. BR
  • Pujatti, Priscilla Brunelli; Instituto Nacional de Câncer José Alencar Gomes da Silva. Medicina Nuclear. Rio de Janeiro. BR
Braz. J. Pharm. Sci. (Online) ; 58: e191058, 2022. tab
Article in English | LILACS | ID: biblio-1383991
ABSTRACT
Abstract Whole-body bone scintigraphy (WB-BS) is used for detecting and monitoring metastatic spread of prostate cancer (PCa) and to investigate bone pain episodes. To investigate the impact of a positive WB-BS on pain-relieving medicine prescription in PCa patients, a single-center, retrospective cohort study with PCa patients classified as positive for bone metastases (BM) by WB-BS was conducted. Demographic, clinical, and ambulatory pain-relieving medicine prescription data were evaluated. Pain-relieving medicines were categorized according to the WHO 'Analgesic Ladder'. Regimens adopted before and after WB-BS were compared. Differences were considered significant at p<0.05. A total of 180 PCa patients were diagnosed with BM, 64.4% of whom were ≥65 years of age. Thirty-three patients were prescribed analgesics only after WB-BS, mostly including NSAIDs and weak opioids. Pain-relieving prescription changed after WB-BS in patients with prescriptions before and after WB-BS, with a reduction in NSAIDs and adjuvants and an increase in weak and strong opioids. In addition, 40% of patients with WHO analgesic step 1 drugs and 21.7% of patients with WHO step 2 drugs before WB-BS changed to other WHO steps after WB-BS. Pain-relieving prescriptions changed after a positive WB-BS, providing evidence that it could contribute to clinical management of painful metastatic PCa patients.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Patients / Prostatic Neoplasms / Radionuclide Imaging / Retrospective Studies / Neoplasm Metastasis Type of study: Diagnostic study / Observational study Limits: Adult / Humans / Male Language: English Journal: Braz. J. Pharm. Sci. (Online) Journal subject: Farmacologia / Terapˆutica / Toxicologia Year: 2022 Type: Article Affiliation country: Brazil Institution/Affiliation country: Instituto Nacional de Câncer José Alencar Gomes da Silva/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Patients / Prostatic Neoplasms / Radionuclide Imaging / Retrospective Studies / Neoplasm Metastasis Type of study: Diagnostic study / Observational study Limits: Adult / Humans / Male Language: English Journal: Braz. J. Pharm. Sci. (Online) Journal subject: Farmacologia / Terapˆutica / Toxicologia Year: 2022 Type: Article Affiliation country: Brazil Institution/Affiliation country: Instituto Nacional de Câncer José Alencar Gomes da Silva/BR